Religion has continued to play an important role in the Nigerian public’s perception of the coronavirus disease and the willingness to take the newly developed vaccine. In an April 2020 NOI Poll Survey conducted to ascertain the public’s perception of the coronavirus pandemic and the Nigerian go...vernment’s initial response to the virus, 42% of respondents who stated that they were immune to coronavirus highlighted their belief in God as their reason, regardless of religious affiliation. Recent public opinion polls have also revealed that although Nigeria has surpassed over 100,000 coronavirus cases, more than a third of Nigerians who are aware of current scientific advances regarding the coronavirus vaccine are unwilling to take it whenever it is eventually made available nationwide. These respondents anchored their hopes on their faith, which for the Nigerian government could signal another public health risk in its efforts to curb the spread of the disease.
more
This document aims to provide global guidance on poliomyelitis (polio) surveillance in the context of the COVID-19 pandemic. It comes as a technical complement to Polio eradication programme continuity, Immunization in the context of COVID-19 pandemic frequently asked questions, and is aligned with ...the Global Polio Eradication Initiative (GPEI) commitment to support the COVID-19 pandemic response.
It highlights the decision making framework to guide the level of polio surveillance activities at country level including; the measures to put in place to ensure a minimum level of polio surveillance in the field and in the laboratory, and the trigger to return to normal polio function.
more
Since May 2019, Confirmation of 4 new emergence of type 2 vaccine-derived poliovirus (VDPV2) in Bambari (2) and Bimbo (2) health districts without any genetic link between them and other known viruses ; Bambari Health District: CAF-RS4-BAM-19-058, onset of paralysis: May 02, 2019. 07 positive contac...ts with the same genetic link. Community samples CAF-RS4-BAM-19-058CC14 and CAF-RS4-BAM-19-058CC17 positive, genetically related to each other but not genetically linked to the CAF-RS4-BAM-19-058 index case (new emergence)
more
Taking the whole of Africa approach to fighting the COVID-19 pandemic has and will continue to require coordinated efforts from multiple stakeholders from across the continent. Africa CDC would like to acknowledge the deep partnership and continued support of AUDA-NEPAD, AVAREF, WHO AFRO, the Bill a...nd Melinda Gates Foundation and the Mastercard Foundation. These partners have helped to shape and drive the continent’s strategic response to the COVID-19 pandemic and have offered support to ensure the continent receives a fair and equitable share of the COVID-19 vaccine without delay.
We look forward to continuing and deepening our partnership for the benefit of the public health of Africa.
more
Learn about the composition and delivery mechanism for the new classes of COVID-19 vaccines based on adenovirus from Johnson & Johnson and AstraZeneca with Dr. Jonathan Genzen, COO of ARUP Laboratories and an Associate Professor at the University of Utah School of Medicine.
This collection of forms (in MS Excel) should be used in training and included in the outbreak response guidelines. The forms include tally sheets, check lists, household assessment and missed children forms. They can be adapted to specific national conditions.
The roadmap describes the actions needed to
achieve the three development goals for TB
vaccines set by the WHO:
1. A safe, effective and affordable TB vaccine
for adolescents and adults.
2. An affordable TB vaccine for neonates and
infants with improved safety and efficacy.
3. A therapeutic v...accine to improve TB
treatment outcomes
more
– з вакциною на білковій основі
(Nuvaxovid® виробництва Novavax)
Станом на: 15 лютого 2022 р. (даний інформаційний лист постійно оновлюється)
AUFKLÄRUNGSMERKBLATT
Zur Schutzimpfung gegen COVID-19 (Cor...ona Virus Disease 2019) (Grundimmunisierung )
– mit proteinbasiertem Impfstoff –
(Nuvaxovid® von Novavax)
Stand: 15. Februar 2022 (dieser Aufklärungsbogen wird laufend aktualisiert)
(Comirnaty® 10 μg bzw. 30 μg von BioNTech/Pfizer und Spikevax® von Moderna)
more
Vaksen MMRV (Lawoujòl, Malmouton,
Ribeyòl, ak Varisèl): Sa Ou Dwe Konnen
La dosis de refuerzo está indicada una vez transcurridos los 4 meses (120 días) de la última dosis del esquema inicial y será con vacuna de plataforma ARNm: Pfizer-BioNTech pediátrica a partir de los 5 años o Moderna para uso pediátrico a partir de los 6 años.